HAEM5:ALK-positive anaplastic large cell lymphoma - Revision history

Bailey.Glen at 15:30, 4 September 2025

2025-09-04T15:30:32Z

← Older revision		Revision as of 10:30, 4 September 2025
Line 849:		Line 849:

	<nowiki>*</nowiki>''Citation of this Page'': “ALK-positive anaplastic large cell lymphoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:ALK-positive_anaplastic_large_cell_lymphoma</nowiki>.		<nowiki>*</nowiki>''Citation of this Page'': “ALK-positive anaplastic large cell lymphoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:ALK-positive_anaplastic_large_cell_lymphoma</nowiki>.
	~~==Other Sections==~~
	Primary Authors*


	~~Miguel Gonzalez Mancera, MD~~

	~~Sumire Kitahara, MD~~

	~~Cedars-Sinai, Los Angeles, CA~~
	~~[[Category:HAEM5]]~~
	~~[[Category:DISEASE]]~~
	~~[[Category:Diseases A]]~~

Bailey.Glen at 15:30, 4 September 2025

2025-09-04T15:30:13Z

← Older revision		Revision as of 10:30, 4 September 2025
Line 46:		Line 46:
	\|}		\|}

	~~==Gene Rearrangements==~~
	==Gene Rearrangements==		==Gene Rearrangements==
	Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Details on clinical significance such as prognosis and other important information can be provided in the notes section. Please include references throughout the table. Do not delete the table.'')</span>		Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Details on clinical significance such as prognosis and other important information can be provided in the notes section. Please include references throughout the table. Do not delete the table.'')</span>

Bailey.Glen at 17:09, 3 July 2025

2025-07-03T17:09:16Z

@@ Line 35: / Line 35: @@
 |ALK-positive anaplastic large cell lymphoma
 |}
 ==Related Terminology==

Bailey.Glen at 21:28, 25 May 2025

2025-05-25T21:28:40Z

← Older revision		Revision as of 16:28, 25 May 2025
Line 140:		Line 140:


	~~'''~~<u>Of note, identifying the ''ALK'' fusion partner is not considered necessary in routine clinical practice.</u>~~'''~~		<u>Of note, identifying the ''ALK'' fusion partner is not considered necessary in routine clinical practice.</u>


Line 348:		Line 348:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 505:		Line 505:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 546:		Line 546:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>''EGFR''		\|<span class="blue-text">EXAMPLE:</span>''EGFR''
Line 591:		Line 591:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene; Genetic Alteration!!~~'''~~Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)~~'''~~!!~~'''~~Prevalence (COSMIC / TCGA / Other)~~'''~~!!~~'''~~Concomitant Mutations~~'''~~!!~~'''~~Mutually Exclusive Mutations~~'''~~		!Gene; Genetic Alteration!!Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)!!Prevalence (COSMIC / TCGA / Other)!!Concomitant Mutations!!Mutually Exclusive Mutations
	!~~'''~~Diagnostic Significance (Yes, No or Unknown)~~'''~~		!Diagnostic Significance (Yes, No or Unknown)
	!Prognostic Significance (Yes, No or Unknown)		!Prognostic Significance (Yes, No or Unknown)
	!Therapeutic Significance (Yes, No or Unknown)		!Therapeutic Significance (Yes, No or Unknown)

Bailey.Glen at 20:05, 25 May 2025

2025-05-25T20:05:00Z

← Older revision		Revision as of 15:05, 25 May 2025
Line 50:		Line 50:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==
	~~<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|Anaplastic large cell lymphoma, ALK-positive
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|N/A
	\|}		\|}

Bailey.Glen at 17:32, 24 March 2025

2025-03-24T17:32:33Z

← Older revision		Revision as of 12:32, 24 March 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:ALK-positive anaplastic large cell lymphoma}}		{{DISPLAYTITLE:ALK-positive anaplastic large cell lymphoma}}

	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

Line 15:		Line 14:

	Sumire Kitahara, MD, Cedars-Sinai, Los Angeles, CA		Sumire Kitahara, MD, Cedars-Sinai, Los Angeles, CA

	~~__TOC__~~

	==WHO Classification of Disease==		==WHO Classification of Disease==

Line 877:		Line 873:

	Cedars-Sinai, Los Angeles, CA		Cedars-Sinai, Los Angeles, CA

	~~__TOC__~~

	[[Category:HAEM5]]		[[Category:HAEM5]]
	[[Category:DISEASE]]		[[Category:DISEASE]]
	[[Category:Diseases A]]		[[Category:Diseases A]]

Bailey.Glen: /* Gene Mutations (SNV/INDEL) */

2025-02-14T01:30:33Z

Gene Mutations (SNV/INDEL)

@@ Line 548: / Line 548: @@
 </blockquote>
 ==Gene Mutations (SNV/INDEL)==
 {| class="wikitable sortable"
@@ Line 656: / Line 698: @@
 ----
 </blockquote>
 ==Epigenomic Alterations==

Bailey.Glen: /* Individual Region Genomic Gain/Loss/LOH */

2025-02-14T01:29:11Z

Individual Region Genomic Gain/Loss/LOH

@@ Line 349: / Line 349: @@
 ==Individual Region Genomic Gain/Loss/LOH==
+Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene rearrangements. Details on clinical significance such as prognosis and other important information can be provided in the notes section. Can refer to CGC workgroup tables as linked on the homepage if applicable. Please include references throughout the table. Do not delete the table.'') </span>
-Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable. Do not delete table.'') </span>
+{| class="wikitable sortable"
 {| class="wikitable sortable"
@@ Line 450: / Line 500: @@
 ----
 </blockquote>
 ==Characteristic Chromosomal or Other Global Mutational Patterns==

Bailey.Glen: /* Gene Rearrangements */

2025-02-14T01:28:14Z

Gene Rearrangements

@@ Line 65: / Line 65: @@
 ==Gene Rearrangements==
 FISH is not required for diagnosis in routine practice <ref name=":27" /><ref name=":28" />.
@@ Line 286: / Line 347: @@
 ----
 </blockquote>
 ==Individual Region Genomic Gain/Loss/LOH==

Jennelleh at 23:43, 13 February 2025

2025-02-13T23:43:05Z

Show changes